Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Common Equity (2019 - 2026)

Alx Oncology Holdings' Common Equity history spans 5 years, with the latest figure at $189.7 million for Q4 2023.

  • On a quarterly basis, Common Equity fell 27.99% to $189.7 million in Q4 2023 year-over-year; TTM through Dec 2023 was $189.7 million, a 27.99% decrease, with the full-year FY2023 number at $189.7 million, down 27.99% from a year prior.
  • Common Equity hit $189.7 million in Q4 2023 for Alx Oncology Holdings, up from $168.8 million in the prior quarter.
  • Over the last five years, Common Equity for ALXO hit a ceiling of $429.8 million in Q4 2020 and a floor of -$84.4 million in Q2 2020.
  • Historically, Common Equity has averaged $206.4 million across 5 years, with a median of $252.0 million in 2020.
  • Biggest five-year swings in Common Equity: soared 708.51% in 2020 and later plummeted 41.19% in 2023.
  • Tracing ALXO's Common Equity over 5 years: stood at -$70.6 million in 2019, then soared by 708.51% to $429.8 million in 2020, then dropped by 15.54% to $363.0 million in 2021, then dropped by 27.43% to $263.5 million in 2022, then decreased by 27.99% to $189.7 million in 2023.
  • Business Quant data shows Common Equity for ALXO at $189.7 million in Q4 2023, $168.8 million in Q3 2023, and $212.7 million in Q2 2023.